News

The prospective, single-arm study is ongoing to evaluate the drug-eluting stent for the treatment of peripheral artery disease (PAD). Results of a separate pivotal randomized study in a

A5 labs is a contract research based organisation servicing the pharmaceutical and biotechnology companies in North America. The company utilises its research capabilities to license and acquire novel

Halozyme has posted a net loss of $11.8m for the first quarter 2010, or $ 0.13 per diluted share, compared to $14.7m, or $ 0.18 per diluted share,

For the first quarter of 2010, Watson Pharmaceuticals posted a net income of $69.8m, or $0.57 per diluted share, compared to $49.1m, or $0.43 per diluted share, for

GenScript said that antibody drug is among the powerful forms of medication. There are research and development activities to develop antibody drugs for numerous serious diseases, such as

NVA237 was licensed to Novartis by Sosei and its co-development partner Vectura Group in a 2005 deal in which the two companies could receive up to $375m in

Valeant Onsolis is an opioid analgesic indicated only for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and

Osiris Therapeutics has posted a net income of $2.4m for the first quarter of 2010, or $0.07 per diluted share, compared to $14.7m, or $0.45 per diluted share,

IntelliCyt said that the new HTFC Screening System, designed to enable large scale, high throughput, high content screening, takes a new approach to cell-based screening by integrating the